Your email and its content will be used to provide you an answerto your message. You have the possibility to access, to modify, to rectify and to suppress any personal data concerning you.
To exercise this right, please click here.
05 February 2014 - Paris (France)
Ipsen announces clinical results of Dysport® Next Generation (DNG) and its intent to file the first ready-to-use liquid toxin A in Europe…